Aurinia Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.10.20	Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com (Businesswire)
02.10.20	Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
28.09.20	Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome (Businesswire)
10.09.20	Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences (Businesswire)
05.09.20	Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
11.08.20	Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights (Businesswire)
04.08.20	Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference (Businesswire)
30.07.20	Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020 (Businesswire)
27.07.20	Aurinia Closes US$200 Million Public Offering of Common Shares (Businesswire)
23.07.20	Pre-market Movers In Healthcare Sector: ENTX, IMRN, CNTG, IMMP... (RTTNews)
23.07.20	Aurinia Prices US$200 Million Public Offering of Common Shares (Businesswire)
22.07.20	Aurinia Announces Public Offering of Common Shares (Businesswire)
22.07.20	Stock Alert: Aurinia Pharma Jumps 11% On Priority Review For Voclosporin (RTTNews)
22.07.20	AUPH Faces FDA In Jan, ARCT To Advance LUNAR-COV19 Vaccine, IFRX On Watch, All Eyes On ALEC (RTTNews)
21.07.20	Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis (Businesswire)
22.06.20	Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome (Businesswire)
05.06.20	Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress (Businesswire)
03.06.20	Aurinia Announces Results of Annual General Meeting (Businesswire)
01.06.20	Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
26.05.20	Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis (Businesswire)
15.05.20	Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference (Businesswire)
14.05.20	Aurinia Reports First Quarter 2020 Financial Results and Recent Operational Highlights (Businesswire)
07.05.20	Aurinia Pharmaceuticals to Release First Quarter 2020 Financial Results on May 14, 2020 (Businesswire)
27.04.20	Aurinia Appoints Joe Miller as Chief Financial Officer (Businesswire)
20.04.20	Aurinia Appoints Industry Veteran Timothy P. Walbert to its Board of Directors (Businesswire)
18.03.20	Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings (Businesswire)
17.03.20	Aurinia Pharmaceuticals Establishes U.S. Commercial Operations Center in Rockville, Maryland (Businesswire)
12.03.20	Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative (Businesswire)
05.03.20	Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights (Businesswire)
03.03.20	Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020 (Businesswire)
25.02.20	Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team (Businesswire)
21.02.20	Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference (Businesswire)
12.12.19	Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares (Businesswire)
10.12.19	APTO On The Move, PLX To Effect Reverse Split, SCYX Plunges (RTTNews)
10.12.19	Aurinia Prices US$166.7 Million Public Offering of Common Shares (Businesswire)
09.12.19	Aurinia Announces Public Offering of Common Shares (Businesswire)
05.12.19	AUPH Soars On Lupus Trial Results, ACAD On Watch, ALNA Trims Workforce (RTTNews)
05.12.19	Aurinia Pharma Shares Surge 125% On Positive Trial Results For Lupus Drug (RTTNews)
04.12.19	Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis (Businesswire)
03.12.19	Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference (Businesswire)
14.11.19	Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights (Businesswire)
13.11.19	Aurinia Announces Updates to the Board of Directors (Businesswire)
07.11.19	Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil (Businesswire)
06.11.19	Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019 (Businesswire)
31.10.19	Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome (Businesswire)
16.10.19	Aurinia Reports Last Patient Study Visit in Aurora Phase 3 Lupus Nephritis Study and Provides Update on ATM Facility (Businesswire)
11.10.19	Healthcare Stocks That Plunged To New Lows(CTXR,AUPH,AAC...) (RTTNews)
11.10.19	5 Top Losers In Healthcare Sector (AKTX, COCP, AUPH…) (RTTNews)
07.10.19	5 Healthcare Stocks Facing Key Catalysts In Q4, 2019 (RTTNews)
26.09.19	Aurinia Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Aurinia Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten